Targeted Radionuclide Therapy

Radioimmunotherapy, also known as systemic targeted radiation therapy, uses antibodies, antibody fragments, or compounds as carriers to guide radiation to the targets. It is a topic rapidly increasing in importance and success in treatment of cancer patients. This book represents a comprehensive amalgamation of the radiation physics, chemistry, radiobiology, tumor models, and clinical data for targeted radionuclide therapy. It outlines the current challenges and provides a glimpse at future directions. With significant advances in cell biology and molecular engineering, many targeting constructs are now available that will safely deliver these highly cytotoxic radionuclides in a targeted fashion.

A companion website includes the full text and an image bank.


Table Of Contents

Part I: IMMUNOLOGY AND TARGETING CONSTRUCTS

1: The Immune System

2: Methods for Development of Monoclonal Antibody Therapeutics

3: Peptides

4: Affibody Molecules for Targeted Radionuclide Therapy

5: Aptamers

Part II: PHYSICS AND RADIOBIOLOGY OF TRT

6: The Physics and Radiobiology of TRT

7: Chelation Chemistry

8: Radiation Dosimetry

9: Microdosimetry

10: Radiation Safety for RT

Part III: TUMOR MICROENVIRONMENT AND DELIVERY STRATEGIES

11: Employing SEREX

12: Antibody Penetration into Tumors

13: Overcoming Barriers Posed by Solid Tumors

14: The Delivery Construct

15: The Type of Radionuclide

16: Pretargeting Strategies for TRT

17: Combined Modality Strategies

18: Extracorporeal Techniques

19: Concept of Systemic Therapy

20: Modeling of the Systemic Cure with TRT

Part IV: UNCONJUGATED THERAPY

21: Thyroid Cancer

22: Unconjugated Radiopharmaceuticals

23: 90-y Microspheres

24: SIRT

Part V: CONJUGATED THERAPY

25: Colorectal Cancer

26: Pancreatic Cancer

27: Hepatobillary Cancer

28: Astrocytoma

29: Medullary Thyroid Cancer

30: Head and Neck Cancer

31: Prostate Cancer

32: Renal Cell Carcinoma

33: Bladder Cancer

34: Leukemia

35: Non-Hodgkin's Lymphoma

36: Hodgkin's Disease

37: Multiple Myeloma

38: Neuroendocrine Tumors

39: Malignancies Treated with Peptides

40: Ovarian Cancer

41: Osteosarcoma

42: Pediatric Tumors

43: Palliation

44: Melanoma